Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

被引：0
|
作者：
Helmut Oettle
Andreas Hilbig
机构：
[1] Berlin,H Oettle is an Associate Professor and A Hilbig is a Clinical Research Fellow in the Department of Medical Oncology and Hematology at the Charité School of Medicine
[2] Germany.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：686 / 687
页数：1
相关论文
共 50 条
  • [31] Does erlotinib improve symptoms in patients with lung cancer?
    David M Jackman
    Pasi A Jänne
    Nature Clinical Practice Oncology, 2007, 4 : 146 - 147
  • [32] Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
    Yang, Zu-Yao
    Yuan, Jin-Qiu
    Di, Meng-Yang
    Zheng, Da-Yong
    Chen, Jin-Zhang
    Ding, Hong
    Wu, Xin-Yin
    Huang, Ya-Fang
    Mao, Chen
    Tang, Jin-Ling
    PLOS ONE, 2013, 8 (03):
  • [33] A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G)
    Iyer, R.
    Khushalani, N.
    Tan, W.
    Litwin, A.
    LeVea, C.
    Hutson, A.
    Tucker, C.
    Ma, W.
    Fakih, M.
    Adjei, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 391 - 391
  • [34] Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in advanced pancreatic cancer patients
    Shinohara, Akira
    Okuyama, Hiroyuki
    Kuwahara, Akiko
    Kobayashi, Misaki
    Takahashi, Hideaki
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Saitoh, Shinichiro
    Ikeda, Masafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer
    Han, B.
    Kim, H. S.
    Choi, D. R.
    Shim, B. Y.
    Lee, K. H.
    Kim, J. W.
    Kim, J. H.
    Kim, H. Y.
    Song, H.
    Zang, D. Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] JCO Flashback: A Comparison of Erlotinib Plus Gemcitabine vs Gemcitabine Alone in Treating Advanced Pancreatic Cancer (2007)
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4713 - 4713
  • [37] Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? - Reply
    Moore, Malcolm J.
    Au, Heather Jane
    Parulekar, Wendy
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) : 4508 - 4508
  • [38] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] Non-interventional study with Erlotinib/Gemcitabine in patients with metastatic pancreatic cancer
    Oettle, H.
    Tessen, H. W.
    Groschek, M.
    Breuer, F.
    Hoeffkes, H. G.
    Kindler, M.
    Marschner, N.
    Schulze, M.
    Steudel, N.
    Waldschmidt, D.
    Heinemann, V
    ONKOLOGIE, 2013, 36 : 123 - 123
  • [40] Erlotinib/gemcitabine improves survival in first-line pancreatic cancer patients
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (11): : 1383 - 1383
12345